Denosumab: A bone antiresorptive drug.

Area of Science:

• Bone Biology and Pharmacology
• Oncology
• Endocrinology

Background:

• Bone remodeling involves osteoclasts and osteoblasts; osteoporosis results from bone mass loss, increasing fracture risk.
• Denosumab is a human monoclonal antibody with antiresorptive properties, distinct from other antiresorptive agents.
• It functions by mimicking osteoprotegerin (OPG), inhibiting the RANKL/RANK pathway crucial for osteoclast function.

Purpose of the Study:

• To evaluate the efficacy and administration of denosumab across various bone-related conditions.
• To highlight denosumab's mechanism of action and its advantages in treatment protocols.
• To detail denosumab's approved indications and dosing regimens.

Main Methods:

• Clinical trials assessing denosumab's efficacy in postmenopausal osteoporosis.
• Evaluation of denosumab's impact on unresectable giant cell tumor of bone.
• Comparative studies of denosumab versus zoledronic acid for skeletal-related events (SREs) in cancer patients.

Main Results:

• Denosumab demonstrated efficacy in postmenopausal osteoporosis and unresectable giant cell tumor of bone.
• It showed a significant effect in non-metastatic prostate cancer, delaying skeletal-related events (SREs).
• Denosumab offers advantages in dosing frequency (twice yearly for osteoporosis, monthly for GCT) and tolerability.

Conclusions:

• Denosumab is an effective antiresorptive agent with a novel mechanism of action.
• Its approved indications include osteoporosis, giant cell tumor of bone, and prevention of SREs in specific cancer patients.
• Denosumab provides convenient dosing and improved tolerability, representing a valuable therapeutic option.